Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia

Minran Zhou; Jiping Zeng; Xiaoming Wang; Xiangyu Wang; Tao Huang; Yue Fu; Ting Sun; Jihui Jia; Chunyan Chen

doi:10.18632/oncotarget.2859

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia

Minran Zhou, Jiping Zeng, Xiaoming Wang, Xiangyu Wang, Tao Huang, Yue Fu, Ting Sun, Jihui Jia and Chunyan Chen _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:1249-1261. https://doi.org/10.18632/oncotarget.2859

Metrics: PDF 2723 views | HTML 2362 views | ?

Abstract

Minran Zhou1, Jiping Zeng2, Xiaoming Wang1, Xiangyu Wang1, Tao Huang1, Yue Fu1, Ting Sun1, Jihui Jia3 and Chunyan Chen1

1 Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, P. R. China

2 Department of Biochemistry, School of Medicine, Shandong University, Jinan, Shandong, P. R. China

3 Department of Microbiology/Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Medicine, Shandong University, Jinan, Shandong, P. R. China

Correspondence:

Chunyan Chen, email:

Keywords: RBP2; miR-21; chronic myeloid leukemia; blast crisis

Received: August 22, 2014 Accepted: November 25, 2014 Published: November 26, 2014

Abstract

Chronic myeloid leukemia in the blastic phase (CML-BP) responds poorly to clinical treatments and is usually fatal. In this study, we found that the histone H3 lysine 4 (H3K4) demethylase RBP2 (also called JARID1A and KDM5A) is underexpressed in CML-BP. The RBP2 histone demethylase stimulates leukemia cell differentiation and inhibits cell proliferation. We identified miR-21 was directly downregulated by RBP2 and found that miR-21 downregulated PDCD4 expression in leukemia cells. By binding to miR-21 promoter and by demethylating of trimethylated H3K4 at the miR-21 locus, RBP2 downregulated miR-21 expression. This in turn activated PDCD4. In conclusion, RBP2 epigenetically downregulated miR-21 in blast transformation of CML.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2859

Publication Alerts

Research Papers:

Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia

Abstract